AA
REGN icon

Armis Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Armis Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$201K Buy
+263
New +$199K 0.02% 488
2026
Q1 		– Sell
-294
Closed -$215K – 474
2025
Q4 		$215K Sell
294
-18
-6% -$12.2K 0.02% 403
2025
Q3 		$200K Buy
+312
New +$176K 0.02% 314

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Armis Advisers's REGN Position: Q3 2026 in Review

Armis Advisers opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 263 shares worth $201K. The stake represents 0.02% of the portfolio and ranks #488 among its holdings. This is a return to the name: Armis Advisers previously reported a position in REGN as recently as Q4 2025.

Armis Advisers first reported a position in REGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $215K in Q4 2025. 182 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Armis Advisers held 263 shares of Regeneron Pharmaceuticals worth $201K as of Q3 2026.
  • Regeneron Pharmaceuticals was a new Armis Advisers position in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.02% of Armis Advisers's portfolio in Q3 2026, its #488 holding.
  • Armis Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Armis Advisers's Regeneron Pharmaceuticals position peaked at $215K in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Armis Advisers's 13F filing for Q3 2026, filed 13 Oct 2026.